Amgen’s AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader ...

If Amgen can secure full approval for Lumakras ahead of the FDA's 14 December decision date for Mirati's drug, it could close off that route to market and force the company to wait for its own ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. Image Source: Zacks Investment Research Amgen’s stock has been rising consistently, with ...

Amgen AMGN reported first-quarter 2025 adjusted ... driven by broad prescribing across both academic and community segments. Lumakras/Lumykras recorded sales of $85 million in the quarter, up ...

Amgen is a leader in biotechnology-based human ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

Amgen said its drug Lumakras met the main goal of a Phase 3 study in non-small cell lung cancer driven by a particular genetic mutation. The pharmaceutical giant offered no specifics, but the ...

Amgen recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages.

The FDA recently approved Amgen's Lumakras in combination with Vectibix as a treatment for colorectal cancer. Amgen even has a GLP-1 weight-loss drug in development. Argus has a "buy" rating and $ ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...